Realworld analysis of GLP1a drugs for weight loss finds low adherence and increased cost in first year

EAGAN, Minn., July 11, 2023 /PRNewswire/ — An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime), and Magellan Rx Management, (Magellan Rx), a Prime Therapeutics company, shows that 68 percent of individuals who newly started glucagon-like peptide-1 agonist (GLP-1a)…Read More